<div id="readability-page-1"><div><ul> <li>In early May 2026, TransMedics Group reported first-quarter 2026 results showing revenue of US$173.93 million, up from US$143.54 million a year earlier, but net income fell to US$7.32 million from US$25.68 million and diluted earnings per share from continuing operations declined to US$0.20 from US$0.70.</li> <li>The company also reiterated its full-year 2026 revenue guidance of US$727 million to US$757 million, signaling confidence in continued top-line expansion even as profitability compressed in the latest quarter.</li> <li>We’ll now examine how reaffirmed full-year revenue guidance alongside weaker quarterly earnings reshapes TransMedics Group’s investment narrative and risk profile.</li> </ul><p>Find 50 companies with promising cash flow potential yet trading below their fair value.</p><h2>TransMedics Group Investment Narrative Recap</h2><p>To own TransMedics Group, you need to believe its Organ Care System and transplant services can keep expanding usage across organs and geographies, despite rising scrutiny, costs, and competition. The latest quarter supports the near term revenue growth story but highlights a key risk: margin pressure as investments and operating costs weigh on earnings. The reaffirmed 2026 revenue guidance suggests the immediate growth catalyst is intact, while the drop in net income underlines how fragile profitability can be in the near term.</p> <p>The most relevant recent announcement here is the reaffirmed full year 2026 revenue guidance of US$727 million to US$757 million, issued alongside Q1 results. That range anchors the growth narrative around higher transplant volumes and broader OCS adoption, even as short term earnings fluctuate. For anyone focused on catalysts such as expanding clinical use and scaling the logistics network, this guidance provides a reference point to judge whether upcoming quarters confirm or challenge the current growth expectations.</p> <p>Yet beneath the reaffirmed growth outlook, investors should be aware of the risk that rising costs and weaker margins could rapidly change how sustainable that story really is...</p> <p>Read the full narrative on TransMedics Group (it's free!)</p><p>TransMedics Group's narrative projects $1.0 billion revenue and $204.2 million earnings by 2029. This requires 18.2% yearly revenue growth and about a $32.3 million earnings increase from $171.9 million today.</p><p>Uncover how TransMedics Group's forecasts yield a $117.89 fair value, a 87% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/637b0610-2ab9-473d-832e-59cae0b3161a/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/637b0610-2ab9-473d-832e-59cae0b3161a/chart/quote-price"/><figcaption>TMDX 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest analysts were already cautious, assuming revenue of about US$1.0 billion and earnings near US$188.9 million by 2029, which is far less upbeat than consensus. In light of Q1’s softer profitability, you should recognize how wide these opinion ranges are and consider that both the optimistic and pessimistic cases may shift as new results come in.</p><p>Explore 7 other fair value estimates on TransMedics Group - why the stock might be worth over 3x more than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your TransMedics Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.</li><li>Our free TransMedics Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TransMedics Group's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Uncover the next big thing with 25 elite penny stocks that balance risk and reward.</li><li>Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if TransMedics Group might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

TMDX

<p>TransMedics Group reported Q1 2026 results with revenue of $173.93 million, up from $143.54 million, but net income fell to $7.32 million from $25.68 million. The company reaffirmed its 2026 revenue guidance of $727 million to $757 million, indicating confidence in growth despite margin pressures. Analysts express mixed views on future earnings, highlighting risks associated with rising costs and fluctuating profitability.</p>

Simplywall

TransMedics

SPDR S&P Biotech

iShares US Medical Devices

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Why TransMedics Group (TMDX) Is Down 6.8% After Mixed Q1 Results And Reaffirmed 2026 Guidance